FOS and breast carcinoma: This is the first work to reveal that casticin treatment inhibited breast cancer cell migration and invasion through down-regulation of the PI3K/Akt signaling pathway and blockage of c-Jun and c-Fos nuclear translocation, which finally resulted in a decrease in MMP-9 expression.